- Decoupled moves in Biotech indices highlight opportunities and challenges
- Rigel's Phase II Rheumatoid Arthritis drug data are good but financing remains a challenge
- Celgene Becomes a Bargain Once Again
- Amylin, Lilly: Another Case of a Panic Driven Sell-Off
- My Model Biotech Picks: What's Hot and What's Not
A. Reza Saadat
ABOUT
A. Reza Saadat has over 14 years of experience in the pharmaceutical industry as a scientist and in finance/business development capacities. He is the co-founder at Centius, a life science consulting and software firm located in Boston, Massachusetts.
Visit his site: Biotechnology Stock (http://biotechnology-stock.blogspot.com/)
Visit his site: Biotechnology Stock (http://biotechnology-stock.blogspot.com/)
SNAPSHOT
- Trading frequency: Infrequent
- Interests: ETFs, Options, Stocks - long, Stocks - short, Tech stocks
COMPANY
Biotechnology Stocks
Blog describing my opinions on individual stocks in the Biotech industry
BLOG
Currently, there are no blog details for A. Reza Saadat.
Book
Currently, there are no book details for A. Reza Saadat.
Latest Comments
more »
Latest comments on A.'s Articles
more »
LATEST ARTICLES & INSTAPOSTS
more »
